NPC 16570

Drug Profile

NPC 16570

Latest Information Update: 21 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scios
  • Class Aminobenzoic acids; Anti-inflammatories; Fluorenes; Immunotherapies; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Encephalomyelitis; Multiple sclerosis; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 21 Nov 2000 No-Development-Reported for Encephalomyelitis in USA (Unknown route)
  • 21 Nov 2000 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
  • 21 Nov 2000 No-Development-Reported for Ulcerative colitis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top